Terms: = Breast cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
23 results:
1. Plasma microRNA-195, -34c, and - 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients.
Rezaei Z; Dastjerdi K; Allahyari A; ShahidSales S; Talebian S; Maharati A; Zangooie A; Zangouei AS; Sadri F; Sargazi S
Toxicol Appl Pharmacol; 2023 Sep; 475():116652. PubMed ID: 37557922
[TBL] [Abstract] [Full Text] [Related]
2. Syringin exerts anti-breast cancer effects through PI3K-AKT and EGFR-RAS-RAF pathways.
Wang F; Yuan C; Liu B; Yang YF; Wu HZ
J Transl Med; 2022 Jul; 20(1):310. PubMed ID: 35794555
[TBL] [Abstract] [Full Text] [Related]
3. Integrative pan-cancer analysis of mek1 aberrations and the potential clinical implications.
Zhou Z; Peng B; Li J; Gao K; Cai Y; Xu Z; Yan Y
Sci Rep; 2021 Sep; 11(1):18366. PubMed ID: 34526571
[TBL] [Abstract] [Full Text] [Related]
4. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract] [Full Text] [Related]
5. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway.
Zhang Q; Lu S; Li T; Yu L; Zhang Y; Zeng H; Qian X; Bi J; Lin Y
J Exp Clin Cancer Res; 2019 Apr; 38(1):173. PubMed ID: 31023337
[TBL] [Abstract] [Full Text] [Related]
6. Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC.
Liu Y; Zhang X; Yang B; Zhuang H; Guo H; Wei W; Li Y; Chen R; Li Y; Zhang N
Cancer Res; 2018 May; 78(9):2219-2232. PubMed ID: 29330146
[TBL] [Abstract] [Full Text] [Related]
7. The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer.
Omarjee S; Jacquemetton J; Poulard C; Rochel N; Dejaegere A; Chebaro Y; Treilleux I; Marangoni E; Corbo L; Romancer ML
Oncogene; 2017 May; 36(18):2503-2514. PubMed ID: 27941878
[TBL] [Abstract] [Full Text] [Related]
8. Ectopic overexpression of filamin C scaffolds mek1/2 and ERK1/2 to promote the progression of human hepatocellular carcinoma.
Yang B; Liu Y; Zhao J; Hei K; Zhuang H; Li Q; Wei W; Chen R; Zhang N; Li Y
Cancer Lett; 2017 Mar; 388():167-176. PubMed ID: 27919788
[TBL] [Abstract] [Full Text] [Related]
9. Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival.
Zimmermann M; Arachchige-Don AP; Donaldson MS; Patriarchi T; Horne MC
Cell Cycle; 2016 Dec; 15(23):3278-3295. PubMed ID: 27753529
[TBL] [Abstract] [Full Text] [Related]
10. Selumetinib suppresses cell proliferation, migration and trigger apoptosis, G1 arrest in triple-negative breast cancer cells.
Zhou Y; Lin S; Tseng KF; Han K; Wang Y; Gan ZH; Min DL; Hu HY
BMC Cancer; 2016 Oct; 16(1):818. PubMed ID: 27769200
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Leo F; Bartels S; Mägel L; Framke T; Büsche G; Jonigk D; Christgen M; Lehmann U; Kreipe H
Virchows Arch; 2016 Aug; 469(2):191-201. PubMed ID: 27220763
[TBL] [Abstract] [Full Text] [Related]
12. MEK-dependent IL-8 induction regulates the invasiveness of triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Tumour Biol; 2016 Apr; 37(4):4991-9. PubMed ID: 26537583
[TBL] [Abstract] [Full Text] [Related]
13. A Her2-let-7-β2-AR circuit affects prognosis in patients with Her2-positive breast cancer.
Liu D; Deng Q; Sun L; Wang T; Yang Z; Chen H; Guo L; Liu Y; Ma Y; Guo N; Shi M
BMC Cancer; 2015 Nov; 15():832. PubMed ID: 26526356
[TBL] [Abstract] [Full Text] [Related]
14. Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathways.
Hu S; Huang L; Meng L; Sun H; Zhang W; Xu Y
Mol Med Rep; 2015 Nov; 12(5):6745-51. PubMed ID: 26502751
[TBL] [Abstract] [Full Text] [Related]
15. Centchroman suppresses breast cancer metastasis by reversing epithelial-mesenchymal transition via downregulation of HER2/ERK1/2/MMP-9 signaling.
Khan S; Shukla S; Sinha S; Lakra AD; Bora HK; Meeran SM
Int J Biochem Cell Biol; 2015 Jan; 58():1-16. PubMed ID: 25448414
[TBL] [Abstract] [Full Text] [Related]
16. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
[TBL] [Abstract] [Full Text] [Related]
17. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Galic V; Coleman RL; Herzog TJ
Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
[TBL] [Abstract] [Full Text] [Related]
18. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract] [Full Text] [Related]
19. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by mek1 regulation of the BH3-only pro-apoptotic protein Bim.
Periyasamy-Thandavan S; Takhar S; Singer A; Dohn MR; Jackson WH; Welborn AE; LeRoith D; Marrero M; Thangaraju M; Huang S; Schoenlein PV
Breast Cancer Res; 2012 Mar; 14(2):R52. PubMed ID: 22429491
[TBL] [Abstract] [Full Text] [Related]
20. mek1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract] [Full Text] [Related]
[Next]
